Salofalk granules n / an kish.rastv. prolong. 500mg 50 pieces

$69.55

Salofalk granules n / an kish.rastv. prolong. 500mg 50 pieces

Quantity:

SKU: 02069418304 Categories: , , Tag:

Description

Composition
Description:
The gastroresistant granules with sustained release of mesalazine in bags of 500 mg
Product form:
in the Box – 50 sachets.
Contraindications
Hypersensitivity, blood disease, liver failure, children’s age (up to 2 years).
Dosage
500 mg
Indications
Ulcerative colitis, Crohn’s disease. Unapproved indications: diverticular disease (diverticulosis and diverticulitis of the colon), chemoprevention of colorectal cancer.
Interaction with other drugs
While appointing possible potentiation of coumarin anticoagulants, increasing methotrexate toxicity, reducing the effect of spironolactone and diuretic furosemide, decreasing the efficacy of rifampicin and probenecid .. Increases hypoglycemic effect of oral antidiabetics – sulfonylurea derivatives.
pharmachologic effect
Pharmacological group:
Anti-inflammatory.
Pharmacodynamics:
Inhibits the synthesis of metabolites of arachidonic acid (PG), neutrophil lipoxygenase activity inhibits migration, phagocytosis and degranulation of neutrophils, lymphocytes, immunoglobulin secretion; binds and destroys free oxygen radicals.
Pharmacokinetics:
Depending on the dosage form and route of administration of mesalazine release occurs in the rectum and colon (enemas, suppositories) or in the terminal part of the small intestine and in the colon (Table.). Tablet begin to dissolve in the small intestine (at pH> 6) through 110-170 m and are completely dissolved after 165-225 min after administration. The rate of dissolution is not affected by changes in pH of the medium caused by the intake of food or other drugs. During passage through the intestines mesalazine gradually released from the tablets, with approximately 15-30% of the drug is released in the ileum, and 70-75% – in the colon. Metabolized (in N-acetyl-5-aminosalicylic acid) are already in the intestinal mucosa and the liver, therefore the plasma concentration is relatively low (after receiving a single dose of 250 mg – 0.5-1.5 ug / ml). Bound to plasma proteins by 43% (metabolite – by 75-83%). In mother’s milk enters (a metabolite) a dose of 0.1%.
Pregnancy and breast-feeding
If you allow the individual course of the disease, in the last 2-4 weeks of pregnancy should stop taking the drug. At the time of treatment it is advisable to discontinue breastfeeding due to lack of sufficient clinical experience with the drug during this period.
side effects
Rare – abdominal pain, diarrhea, flatulence, headaches and dizziness, allergic reactions, in rare cases – interstitial nephritis, systemic lupus erythematosus syndrome, infants, and thrombocytopenia.
special instructions
The drug is recommended for use only under medical supervision. Prior to treatment, during treatment (14 days after its start, and then – every 4 weeks), as well as after the end of treatment (every 3 months) should be carried out blood tests and urine tests. To monitor the renal function is recommended determination of urea and creatinine in serum, urine sediment.
Dosing and Administration
The granules can be taken without regard to meals. For the treatment of mild and moderate ulcerative colitis and Crohn’s disease the drug is administered in a dose of 1.5-3 g / day in 3 divided doses, in severe cases, the daily dose may be increased to 4-8 g (for not more than 8-12 weeks ). For the prevention of recurrence of drug administered orally at a dose of 1.5 g / d (by applying it as necessary for a few years), or the combined tablets or pellets (1 g / day) with candles (500 mg at night).
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Dr. Falke

There are no reviews yet.

Add your review